- Home
- INSM vs EQR Comparison
INSM vs EQR Comparison
Compare INSM & EQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- EQR
- Stock Information
- Founded
- INSM 1988
- EQR 1993
- Country
- INSM United States
- EQR United States
- Employees
- INSM N/A
- EQR N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- EQR Real Estate Investment Trusts
- Sector
- INSM Health Care
- EQR Real Estate
- Exchange
- INSM Nasdaq
- EQR Nasdaq
- Market Cap
- INSM 26.0B
- EQR 23.8B
- IPO Year
- INSM 2000
- EQR 1993
- Fundamental
- Price
- INSM $127.80
- EQR $64.12
- Analyst Decision
- INSM Strong Buy
- EQR Buy
- Analyst Count
- INSM 17
- EQR 14
- Target Price
- INSM $137.40
- EQR $77.61
- AVG Volume (30 Days)
- INSM 3.0M
- EQR 2.4M
- Earning Date
- INSM 08-07-2025
- EQR 08-04-2025
- Dividend Yield
- INSM N/A
- EQR 4.32%
- EPS Growth
- INSM N/A
- EQR 5.58
- EPS
- INSM N/A
- EQR 2.65
- Revenue
- INSM $398,105,000.00
- EQR $3,044,764,000.00
- Revenue This Year
- INSM $28.23
- EQR $5.13
- Revenue Next Year
- INSM $119.99
- EQR $4.28
- P/E Ratio
- INSM N/A
- EQR $24.16
- Revenue Growth
- INSM 21.15
- EQR 4.40
- 52 Week Low
- INSM $60.40
- EQR $59.41
- 52 Week High
- INSM $128.48
- EQR $78.84
- Technical
- Relative Strength Index (RSI)
- INSM 85.01
- EQR 45.28
- Support Level
- INSM $106.54
- EQR $62.09
- Resistance Level
- INSM $128.48
- EQR $64.03
- Average True Range (ATR)
- INSM 4.11
- EQR 1.32
- MACD
- INSM 1.68
- EQR 0.05
- Stochastic Oscillator
- INSM 97.41
- EQR 39.30
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 312 apartment communities with over 84,000 units and is developing two additional properties with 655 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.